medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2000, Number 4

<< Back

Salud Mental 2000; 23 (4)

El proyecto del genoma humano y su impacto en la psiquiatría

Lóyzaga C, Nicolini H

Language: Spanish
References: 71
Page: 45-50
PDF size: 136.95 Kb.


ABSTRACT

The pharmacological management of OCD is based in the serotonin reuptake inhibitors (SRI), which are effective and safe. The SRI are as effective as clorimipramine, produce less collateral effects, are well tolerated and produce more attachment. Their antiobsessive efficacy is independent of their antidepressive actions. It has been suggested that high scores in compulsions predict a poor answer to treatment. For resistant, refractory or comorbidity cases, a combination of defferent SRSI, benzodiazepins or boosters, such as litio or antipysychotics, like risperidona or haloperidol have been used with relative success. The use of litio is controversial, yet it seems to be useful as a boosters in 15 to 30% of the patients. The combination of SIRS with antipsychotics was first used in patients with OCD and psychotic symptoms, although they are now used in resistant patients. The pharmacological treatment of OCD children is based in the use of SRSI. It is safe, efficient and well tolerated in this group of age. We describe the pharmacological features and the clinical answer of the medications used in OCD.


REFERENCES

  1. AKERMAN DL, GREENLAND S, BYSTRISKY A: A side effects as predictors of drug response in obsessive compulsive disorder. J Clin Psychopharmacol, 19(5):459- 465, 1999.

  2. ALARCON R, WESLEY J, SPITTER D: A predictive study of obsessive-compulsive disorder response to clorimipramine. J Clin Psycopharmacol, 13(3):210-213, 1993.

  3. ALDERMAN J, WOLKOW R, CHUNG M, JOHNSTONE HF: Sertraline treatment of child and adolescent with OCD or depression. J Am Acad Child Adolesc Psychiatry, 37(4):386-394, 1998.

  4. BARR L, GOODMAN W, PRICE L: The serotonine hypotheses of obsessive-compulsive disorder: implications of pharmacological challenge studies. J Clin Psy, 53 (Supl) 4:17-28, 1992.

  5. BENKELFAT CH, MURPHY D, ZOHAR J: Clorimipramine in obsessive-compulsive disorder: further evidence for a serotoninergic mechanism of action. Arch Gen Psy, 46:23-28, 1989.

  6. BISSERBE JC, LANE RM, FLAMENT MF: A double blind comparison of sertralina and clorimipramina in outpatients with obsessive compulsive disorder. European Psychiatry 12(2):82-93, 1997.

  7. CARRASCO J, VIOLLANDER E, SCHNFIIER F: Treatment outcome of obsessive compulsive disorder with comorbid social phobia. J Clin Psy, 53(11):387-391, 1992.

  8. CASSADY S, THAKER G: Addition of fluoxetine to clozapine. Am J Psy, 149(9):1274, 1992.

  9. CAVENDINI P, ERZEGOVESI S, RONCHI P, BELLODI L: Predictive value if obsessive compulsive personality disorder in antiobsessional treatment. European Psychopharmacology, 7(1):45-49, 1997.

  10. CHOUINARD G: Sertraline in the treatment of obsessivecompulsive disorders: two double-blind, placebo control led studies. Int Clin Psychopharmacol, 7 (Supl 2):37-41, 1992.

  11. CLOMIPRAMINE COLLABORATIVE STUDY GROUP: Clorimipramine hidrochioride in the treatment of patients with obsessive-conpulsive disorder. Arch Gen Psy, 48(8):730-738, 1991.

  12. DOMINGUEZ R: Serotoninergic antidepressants and their efficacy in obsessive-compulsive disorder. J Clin Psy, (Supl 53):56-59, 1992.

  13. FLAMENT MF, BISSERBERG JC: Pharmacological treatment of obsessive compulsive disorder. Comparative studies. J Clin Psy, 58(12) Supl:18-22, 1997.

  14. FITZGERALD KD, STEWART CM, TAWILE V, ROSSENBERG DR: J Child Adolesc Pharmacol, 9,(2):115-123,1999.

  15. GRADY T, PIGOTT T, LIEUREUX F: Double blind study of adjuvant buspirone or flouxetine treated patients with obsessive-compulsive disorder. Am J Psy, 150(5):819-821, 1993.

  16. GREIST J: Treating the anxiety: therapeutic options in obsessive-compulsive disorder. J Clin Psy, 51(Supl.11):29-34, 1990.

  17. GREIST JH, JEFFERSON JW: Pharmacotherapy for obsessive-compulsive disorder. Brit J Psy, 173, supl. 35: 64-70, 1998.

  18. GO FS, MALLEY E, BAIRMAHER B, ROSENBERG DF: Manic behaviors associated with fluoxetine in three 12 to 18 years old with absessive-compulsive disorder. J Child Adolesc Psychopharmacol, 8(19):73-80, 1998.

  19. GOODMAN VV, PRICE L, DELGADO P:Specificity of serotonin reuptake inhibitors in the treatment of obsessivecompulsive disorder. Comparison of fluvoxamine and desimipramine. Arch Gen Psy, 47(6):577-585, 1990.

  20. GOODMAN W, PRICE L, RASMUSSEN S: Efficacy of fluvoxamine in obsessive-compulsive disorder. Am J Psy, 146:1001-1005, 1989.

  21. HAY P, SACHDEV P, CUMMING S: Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psy Scand, 87:187-207, 1993.

  22. HOLLANDER E, MULLEN A, DE CARIA C: Obsessivecompulsive disorder, depression and fluoxetine. J Clin Psy, 52:410-422, 1991.

  23. HOLLANDER E, STEIN D, DE CARIA C: A pilot study of biological predictors of treatment outcome in obsessivecompulsive disorder. Biol Psy, 33:747-749, 1993.

  24. INSEL T, MUELLER E, ALTERMAN L: Obsessivecompulsive disorder and serotonina is there a connection? Bio Psy, 20:1174-1185, 1985.

  25. JACOBSE FM: Risperidone in treatment of affective illness and obsessive-compulsive disorder. J Clin Psy, 56(9):423-429, 1995.

  26. JENIKE N, BAER L, BUTTOLPH L: Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psy, 52(1):13-14, 1991.

  27. JENIKE M, HYIAN S, BAER L: A controled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotorengic theory. Am J Psy, 147(9):1209-1215, 1990.

  28. JENIKE M: Approaches to the patient with treatment refractory obsessive-compulsive disorder. J Clin Psy, 51(2 Supl.):15-21, 1990.

  29. JENIKE M: Pharmacological treatment of obsessivecompulsive disorder. Psy Clin NA, 53(Supl 4):29-37, 1992.

  30. JENIKE M, BAER L, GREIST J: Clomipramine vs fluoxetine in obsessive-compulsive disorder. A retrospective comparison of side effects and efficacy. Clin Psychopharinacol, 10(2):122-124, 1990.

  31. JENIKE M, BAER L, SUMMERGPAD P: Sertraline in obsessive-compulsive disorder: a double blind comparison with placebo. Am J Psy, 147(7):278-281, 1990.

  32. JOUBERT AF, STEIN DJ: Citalopram and anxiety disorders. Reviews in Contemporary Pharmachoterapy, 10(2):131, 1999.

  33. KOPONEN H, LEPOLE U, LEINONEN E, JOKINEN R, PENTTINEN J, TURTONEN J: Citalopram in the treatmen of OCD: An open pilot study. Acta Psychiatr Scand, 96(5):343-346, 1997.

  34. KRONING MH, APTER J, SNIS G, BYSTRISKY A, CURTIS A, FERGUSO J, LANDBLOOM R, MUNJACK D, RIESENBERG R, ROBINSON D, ROYBERNE P, PHILLIPS K: Placebo controlled multicentric study of sertralina treatment for OCD. J Clin Psy, 19(2):172-176, 1999.

  35. KELLY M, MYERS C: Clorimipramine: a tryciclic antidepressant effective in obsessive-compulsive disorder. Pharmacotherapy, 24:739-744, 1990.

  36. LAID LK: Issues in the monotherapy and pharmacotherapy of obsessive-compulsive disorder. Psychopharmacol Bull, 32(4):569-578, 1998.

  37. LEONARD H, RAPOPORT J: Pharmacotherapy of childhood obsessive-compulsive disorder. Psy Clin NA, 12(4):962-970, 1989.

  38. LEONARD H, SWEDO S, RAPOPORT J: Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. Arch Gen Psy, 46:1088-1092, 1989.

  39. LEONARD HL, KELLER MB, GORMAN J, HIRSCHFELD RM, YONKERS KA, WEINBERG N: New development in the treatment of obsessive-compulsive disorder. J Clin Psy, 58 (Supl 14):39-45, 1997.

  40. LIEBERMAN J: Evidence for a biological hypothesis of obsessive-compulsive disorder. Neuropsychobiology, 11:14-21, 1984.

  41. MATIX-COLS D, RAUCH SL, MANZO PA, JENIKE MA, BEAR L: Use of factor analuzed sympton dimensions to predict outcome with serotonine reuptake inhibitors and placebo in treatment of obsessive-compulsive disorder. Am J Psy, 159(9):1409-1416, 1999.

  42. MCDOUGLE C, GOODMAN W, LECKMAN J: Haloperidol addition in fluvoxamina refractory obsessive-compulsive disorder. A double blind, placebo controlled study in patients with and without tics. Arch Gen Psy, 51(4):302-308, 1994.

  43. MCDOUGLE C, GOODMAN W, LECKMAN J: Limited therapeutic effects of addition of buspirone fluvoxamine refractory obsessive-compulsive disorder. Arch Gen Psy, 150(4):647-649, 1993.

  44. MCDOUGLE C, GOODMAN W, PRICE L: Neuroleptic additon in fluvoxamina refractory obsessive-compulsive disorder. Am J Psy 147(5):652-654, 1990.

  45. MCDOUGLE C, PRICE L, GOODMAN W: A controlled trial of lithium augmentation in fluvoxamine refractory obsessive- compulsive disorder: lack of efficacy. J Clin Psycopharmacol, 11(3):175-184, 1991.

  46. MINDUS P, JENIKE M: Treatment of malignant obsessivecompulsive disorder. Psy Clin NA, 15(4):921-938, 1992.

  47. MONTGOMERY S, MANCEAUX A: A fluvoxamine in the treatment of obsessive compulsive disorder. Int Clin Psychopharmacol, 7(Supl 1):5-9, 1992.

  48. MUNDO E, BIANCHI L, BELLODI L: Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder. A single blind study. J Clin Psychopharmacol, 17(4):267-271, 1997.

  49. NICOLINI H, MEJIA J, MERINO J: Estudio del paciente obsesivo-compulsivo en una muestra mexicana. Experiencia del Instituto Mexicano de Psiquiatría. Salud Mental 15(4):1-11, 1992.

  50. NICOLINI H, SANDOVAL J: Tratamiento con clorimipramina en un caso severo de trastorno obsesivo-compulsivo. Psiquiatría. 2a. Epoca, 7(2):66-69, 1991.

  51. PATO M, PIGOTT T, HILL J y cols: Controlled comparison of buspirone and clorimipramine in obsessive-compulsive disorder. Am J Psy, 148(1):127-129, 1991.

  52. PATO MT, ZOHAR-KADOUCH R, ZOHAR J, MURPHY DL y cols: Return of symptoms after discontinuation of clorimipramine in patients with obsessive-compulsive disorder. Am J Psy, 145(2):1521-1525, 1988.

  53. PATO MT: Beyond depression: Citalopram for obsessivecompulsive disorder. Int Clin Psy, 14 Supl(2):19-26, 1999.

  54. PIGOTT T, LHEUREUX F, HILL J: A double-blind study of adjuvant buspirone hydrochloride in clorimipramine treated patients with obsessive-compulsive ddisorder. J Clin Psycopharmacol, 12(1):11-18, 1992.

  55. PIGOTT T, PATO MT, BERNSTEIN S: Controlled comparisons of clorimipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psy, 47:926- 932, 1990.

  56. PIGOTT TA, SEAY SM: A review of efficacy of selective serotonine uptake in obsessive-compulsive disorder. J Clin Psy, 69(2):101-106, 1999.

  57. RAVIZZA L, MAINA SM, BOGGETO F, ALBERT U, BARZEGA G, BELLINO S: Long treatment of obsessivecompulsive disorder. CNS Drugs, 10(4):245-255, 1998.

  58. RAVIZZA L, MAINA SM, BOGGETO F, ALBERT U, BARZEGA G, BELLINO S: Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder. Psychopharmacol Bull, 32(4):677-682,1996.

  59. RASMUSSEN S: Lithium and tryptophan augmentation in clorimipramine resistant obsessive-compulsive disorder. Am J Psy, 141:1283-1285, 1984.

  60. RASMUSSEN S, EISEN JL: Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psy, 58 Supl 13:9-13, 1997.

  61. ROSENBERG DR, STEWART CM, FITZGERALD KD, TAWLE V, CARROLL E: Paroxetine open label treatment of pediatric patients with obsessive-compulsive disorder. J Am Acad Child Adolesc Psy, 38(9):73-80, 1999.

  62. SAXENA S, WANG D, BYSTRITSKY A, BAXTER L: Risperidone augmentation of SRI treatment for refractory obsessive- compulsive disorder. J Clin Psychiatry, 57:7, 1996.

  63. STEIN D, HOLLANDER E, ANTHONY D: Serotoninergic medications for sexual obsessions, sexual addictions, and paraphilias. J Clin Psy, 53(8):267-271, 1992.

  64. STEIN DJ, BOUWER C, HWAKRIDGE S, EMSLEY RA: Risperidone augmentation of serotonine reuptake inhibitors in obsessive-compulsive and related disorder. J Clin Psy, 58(3):119-122, 1997.

  65. STERNLICHT H: Obsessive-compulsive disorder, fluoxetine, and buspirone. Am J Psy, 150(3):526, 1993.

  66. THOMSEN PH: Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial 23 cases. J Child Adolesc Psychopharmacol, 7,(3):157-166, 1997.

  67. THORE P, ASBERG M, BERTELSSON: Clorimipramine treatment of obsessive-compulsive disorder: biochemical aspects. Arch Gen Psy, 37:1289-1294, 1980.

  68. VIETA E, BERNARDO M: Antidepressant-induced mania in obsessive-compulsive disorder. Am J Psy, 149(9):1282, 1992.

  69. WARNEKE L: Intravenous clorimipramine therapy in obsessive-compulsive disorder. Can J Psy, 34:853-859,1989.

  70. WINSLOW J, INSEL T: Neurobiology of obsessivecompulsive disorder: a possible role for serotonin. J Clin Psy, 51(8 Supl):27-31, 1990.

  71. WEISS E, POTENZA M, MCDOUGLE C, EPPERSON N: Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open label case series. J Clin Psychiatry, 60:8, 1999.




2020     |     www.medigraphic.com